search button
Open Access

Early mortality in acute promyelocytic leukemia: Potential predictors (Review)

  • Authors:
    • Can Chen
    • Xilian Huang
    • Kaile Wang
    • Kuang Chen
    • Danquan Gao
    • Shenxian Qian

  • View Affiliations

  • Published online on: January 24, 2018     https://doi.org/10.3892/ol.2018.7854
  • Pages: 4061-4069

  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Acute promyelocytic leukemia (APL) is a rare leukemia characterized by the balanced reciprocal translocation between the promyelocytic leukemia gene on chromosome 15 and the retinoic acid receptor α (RARα) gene on chromosome 17, and accounts for 10‑15% of newly diagnosed acute myeloid leukemia each year. The combined use of all‑trans retinoic acid and arsenic trioxide (ATO) as primary therapy has markedly improved the survival rate of patients with APL. Mortality in the first 30 days following therapy remains a major contribution to treatment failure. In the present study, published data was reviewed with a focus on the factors associated with early mortality. When treated with ATO as a primary treatment, the fms‑like tyrosine kinase‑internal tandem deletion has no impact on early mortality. Low lymphoid enhancer binding factor‑1 expression may be a reliable marker for early mortality and the target of therapy if it could be proven by further studies. Cluster of differentiation (CD)56+ and CD34+/CD2+ may be candidates to select high‑risk patients. The risk of early mortality in APL still cannot be predicted via the cell surface makers, despite multiple studies on their prognostic significance. Typically, a complex translocation did not alter the survival rate in patients with APL; however, if an abnormal karyotype [e.g., Ide(17), ZBTB16/ RARα and STAT5B/RARα] appeared singularly or as part of a complex mutation, there is a high possibility of early mortality if clinicians are unable to identify or monitor it.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Chen C, Huang X, Wang K, Chen K, Gao D and Qian S: Early mortality in acute promyelocytic leukemia: Potential predictors (Review). Oncol Lett 15: 4061-4069, 2018.
APA
Chen, C., Huang, X., Wang, K., Chen, K., Gao, D., & Qian, S. (2018). Early mortality in acute promyelocytic leukemia: Potential predictors (Review). Oncology Letters, 15, 4061-4069. https://doi.org/10.3892/ol.2018.7854
MLA
Chen, C., Huang, X., Wang, K., Chen, K., Gao, D., Qian, S."Early mortality in acute promyelocytic leukemia: Potential predictors (Review)". Oncology Letters 15.4 (2018): 4061-4069.
Chicago
Chen, C., Huang, X., Wang, K., Chen, K., Gao, D., Qian, S."Early mortality in acute promyelocytic leukemia: Potential predictors (Review)". Oncology Letters 15, no. 4 (2018): 4061-4069. https://doi.org/10.3892/ol.2018.7854